永安藥業(002365.SZ):控股子公司獲取食品生產許可證
格隆匯3月6日丨永安藥業(002365.SZ)公佈,控股子公司湖北凌安科技有限公司收到潛江市市場監督管理局頒發的《食品生產許可證》,此前,凌安科技主要生產和銷售聚羥酸系減水劑單體和減水劑。近年來由於基建行業不景氣,凌安科技經營業績出現了虧損。爲了走出困境,凌安科技積極進行新產品開發和業務轉型工作,新上了一條“一水肌酸”生產線,目前該生產線已投料試車,即將進入項目驗收階段。本次《食品生產許可證》的取得,表明凌安科技已具備特殊膳食食品的生產資質,進一步拓寬了凌安科技的業務領域,有助於增強凌安科技的市場競爭力和整體抗風險能力,爲凌安科技的可持續發展奠定堅實基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.